Kelonia Therapeutics Announces Late-Breaking Oral Presentation of First-in-Human Data from in vivo BCMA CAR-T Therapy at the American Society of Hematology (ASH) 2025 Annual Meeting

Early results from the Phase 1 inMMyCAR™ study demonstrate ongoing MRD-negative responses in all patients with a tolerable safety profile

Robust CAR-T cell expansion occurred in the absence of preparative chemotherapy

Persistent, memory CAR-T cells in all patients

Excerpt from the Press Release:

BOSTON–(BUSINESS WIRE)–Kelonia Therapeutics, Inc., a clinical-stage biotechnology company pioneering in vivo gene delivery, today announced that its first results from the ongoing inMMyCAR study, a Phase 1 clinical trial evaluating KLN-1010, a novel in vivo gene therapy that generates anti-BCMA CAR-T cells in patients with relapsed and refractory multiple myeloma, will be presented in a late-breaking oral presentation at the American Society of Hematology (ASH) 2025 Annual Meeting in Orlando, Florida.

The late-breaking abstract features results from the first three patients treated with KLN-1010. All patients achieved minimal residual disease (MRD) negativity at month 1 that persisted through three months in the patient with the longest follow up. CAR-T cell expansion and persistence of memory CAR-T cells occurred without the use of lymphodepleting chemotherapy, apheresis, or ex vivo cell manufacturing.

“KLN-1010 is beginning to show the extraordinary clinical outcomes that may be possible with in vivo CAR-T therapy — early, deep responses from a single infusion without the barriers that limit access to traditional CAR-T treatments,” said Kevin Friedman, Ph.D., Chief Executive Officer and Founder of Kelonia.

Click the button below to read the entire Press Release:

Continue Reading The Press Release